Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma
Active Project Grant Awarded Last action
- Award ID
- R44CA298512
- Recipient
-
Celdara Medical, LLC UEI MMVKQXZUBMQ7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,532,139
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 78% complete
- Originally
- Place of performance
- Lebanon, NH 03766, USA
Award details come from USAspending.gov.
Description
- Abstract
- Melanoma incidence is increasing at an alarming rate; as the deadliest of all skin cancers, IT is estimated that one person, every hour of every day, dies of melanoma. Interleukin-2 (IL-2) was the first effective cancer immunotherapy, approved for metastatic renal cancer in 1992 and metastatic melanoma in 1998. IL-2 plays a central role in suppressing or activating lymphocyte responses through differential binding to IL-2 receptors expressed on regulatory t-cells or CD8 cytotoxic t-cells, and NK cells, respectively. Engineering selective IL-2 activity, however, has posed a significant challenge for generating effective immunotherapies lacking substantial toxicity. We are developing CM-HZ01 as a high avidity IL-2 super-agonist that preferentially promotes CD8 effector t-cell expansion and improves anti-tumor activity. In this direct to phase II application, we seek to advance CM-HZ01 to IND for metastatic melanoma, providing a best-in-class therapeutic for patients with limited effective treatment options.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,024,401 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $203,935 | |
| Amendment | $203,935 | |
| Amendment | $1,024,967 | |
| Amendment | $1,024,967 | |
| Amendment | $1,024,967 | |
| Original award | $1,024,967 |
Quick answers
Who received award R44CA298512?
R44CA298512 was awarded to Celdara Medical, LLC by National Cancer Institute (National Institutes of Health) on January 1, 2025.
How much is award R44CA298512 worth?
$5,532,139 has been obligated on R44CA298512.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award